VolitionRx (NYSE:VNRX) Earns “Buy” Rating from D. Boral Capital

VolitionRx (NYSE:VNRX)‘s stock had its “buy” rating reiterated by D. Boral Capital in a report issued on Wednesday,Benzinga reports. They currently have a $5.00 target price on the stock.

Other equities analysts also recently issued reports about the company. Benchmark reissued a “hold” rating on shares of VolitionRx in a research report on Friday, November 22nd. StockNews.com started coverage on shares of VolitionRx in a report on Tuesday. They issued a “sell” rating on the stock.

VolitionRx Stock Down 1.5 %

NYSE:VNRX traded down $0.01 during mid-day trading on Wednesday, reaching $0.65. The company’s stock had a trading volume of 29,923 shares, compared to its average volume of 83,660. VolitionRx has a 1 year low of $0.43 and a 1 year high of $1.23. The firm has a market capitalization of $60.23 million, a PE ratio of -1.81 and a beta of 1.20. The stock has a fifty day moving average of $0.65 and a 200-day moving average of $0.66.

Insider Transactions at VolitionRx

In related news, CEO Cameron John Reynolds purchased 139,811 shares of VolitionRx stock in a transaction dated Monday, December 9th. The stock was bought at an average cost of $0.57 per share, for a total transaction of $79,692.27. Following the transaction, the chief executive officer now owns 2,117,404 shares in the company, valued at approximately $1,206,920.28. The trade was a 7.07 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Guy Archibald Innes acquired 174,764 shares of the firm’s stock in a transaction that occurred on Monday, December 9th. The stock was acquired at an average price of $0.57 per share, for a total transaction of $99,615.48. Following the completion of the transaction, the director now directly owns 617,085 shares in the company, valued at approximately $351,738.45. This represents a 39.51 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Over the last 90 days, insiders have purchased 358,266 shares of company stock valued at $204,212. 12.80% of the stock is currently owned by company insiders.

Institutional Trading of VolitionRx

A hedge fund recently raised its stake in VolitionRx stock. Geode Capital Management LLC lifted its stake in shares of VolitionRx Limited (NYSE:VNRX) by 15.1% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 730,448 shares of the company’s stock after buying an additional 95,900 shares during the quarter. Geode Capital Management LLC owned approximately 0.79% of VolitionRx worth $439,000 as of its most recent filing with the Securities and Exchange Commission. 8.09% of the stock is currently owned by institutional investors and hedge funds.

About VolitionRx

VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes.